Association between time to progression and subsequent survival inceritinib-treated patients with advanced ALK-positive non-small-cell lung cancer

<b>Objective:</b> Time to progression (TTP) is a surrogate marker of overall survival (OS). However, OS is also dependent on post-progression survival (PPS). This study evaluated the association between TTP and the duration of PPS among adult patients who received ceritinib (Zykadia¹) for the treatment of advanced anaplastic lymphoma kinase positive (ALK+) non-small-cell lung cancer (NSCLC). <b>Research design and methods:</b> A pooled analysis was performed on 181 ASCEND-1 (phase I) and ASCEND-2 (phase II) patients who experienced disease progression while on ceritinib. TTP was assessed on its association with PPS in a Kaplan–Meier analysis and in Cox proportional hazard models, adjusted for clinical covariates. <b>Main outcome measures:</b> Main outcomes measured include TTP, PPS, and OS. <b>Results:</b> Patients with TTP ≥6 months experienced significantly longer PPS compared to those with TTP &lt;6 months (median: 9.8 vs. 6.5 months, log-rank <i>p</i>-value <b>Conclusions:</b> A longer duration of TTP after treatment with ceritinib was significantly associated with a longer duration of both PPS and OS.